Press Release: Sanofi in discussions to sell a controlling stake in Opella

Core Viewpoint - Sanofi is in negotiations to sell a 50% controlling stake in its consumer healthcare business, Opella, to CD&R, with further updates expected as discussions progress [1] Group 1: Company Overview - Opella is headquartered in France, employs over 11,000 people, operates in 100 countries, and manages 13 manufacturing sites and four research centers [2] - The company has a portfolio of 100 leading brands, including Allegra, Doliprane, Novanight, Icy Hot, and Dulcolax, making it the third-largest player in the over-the-counter and vitamins, minerals, and supplements market, serving over 500 million consumers globally [2] Group 2: Strategic Alignment - The potential separation of Opella aligns with Sanofi's strategy to focus on innovative medicines and vaccines, as Opella currently operates as a standalone business unit within Sanofi [3] - Opella has dedicated resources for R&D, production, and digital initiatives, along with its own sustainability roadmap, achieving a sales growth of 6.3% at constant exchange rates in 2023 [3]